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THE COVID CRASH: LESSONS LEARNED FROM A WORLD ON PAUSE

COVID-19 and thrombosis: searching for evidence
Division of Hospital Medicine, Henry Ford Health System, Detroit, MI; 2Department of Internal Medicine, Henry Ford Health System, Detroit, MI;
Division of Hematology, Thomas Jefferson University, Philadelphia, PA
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Early in the pandemic, COVID-19-related increases in rates of venous and arterial thromboembolism were seen. Many
observational studies suggested a benefit of prophylactic anticoagulation for hospitalized patients using various dosing
strategies. Randomized trials were initiated to compare the efficacy of these different options in acutely ill and critically
ill inpatients as the concept of immune-mediated inflammatory microthrombosis emerged. We present a case-based
review of how we approach thromboembolic prophylaxis in COVID-19 and briefly discuss the epidemiology, the pathophysiology, and the rare occurrence of vaccine-induced thrombotic thrombocytopenia.

LEARNING OBJECTIVES
• Appreciate the incidence, risk factors, and pathophysiology of thrombosis in COVID19 infection
• Accurately prescribe anticoagulation prophylaxis before, during, and after hospitalization
• Be able to recognize and diagnose vaccineinduced immune thrombotic thrombocytopenia

CLINICAL CASE
A 62yearold physician had been rounding on the
COVID19 ward early in the pandemic (April 2020) and con
tracted the disease. After 1 week, he became hypoxic and
was admitted to the general medical floor, requiring 3L
nasal oxygen. He had no major comorbidities and received
prophylacticdose lowmolecularweight heparin (LMWH).

Introduction
COVID19 infection clearly increases the risk of thrombotic
events for hospitalized patients, but rates of reported inci
dence have varied. A metaanalysis of retrospective studies
involving 64 503 patients showed that deep vein thrombo
sis (DVT) had an overall prevalence of 11.2% and pulmonary
embolism (PE) of 7.8% in those needing hospitalization.1
Pooled rates of venous thromboembolism (VTE) were
higher in the intensive care unit (ICU) setting (27.9% vs 7.1%
in the ward).2 Studies screening patients for VTE reported
a prevalence rate of 25.2% compared to a rate of 12.7%
in those testing only symptomatic patients.1 When more
than 95% of the hospitalized patients received pharmaco
logic VTE prophylaxis, rates were lower, at 3.1% for non
ICU patients and 7.6% for ICU patients.3 Venous or arterial
thrombosis was independently associated with higher
mortality risk (hazard ratio [HR], 1.82; 95% CI, 1.54-2.15;

P <.001).4 Increased arterial thrombotic events were also
reported during hospitalization, with a prevalence of 3.9%
for coronary artery events and 1.6% for stroke.1 Acute
limb ischemia was reported in 0.3% to 1% of hospital
ized patients, predominantly affecting men, with 18% of
patients suffering limb loss.5
Rates of postdischarge VTE in COVID19 patients, how
ever, were not as high. In a cohort from California, VTE
rates in COVID19 patients were no higher than patients
testing negative for COVID19 (1.8% vs 2.2%; P =.16).6 A
pre/postpandemic comparison of postdischarge VTE did
not show a statistically significant risk of VTE in COVID19
patients (odds ratio, 1.6; 95% CI, 0.77-3.1).7

Pathophysiology of thrombosis in COVID-19 infection
The coagulopathy of COVID19 infection is complex, involv
ing an interplay between endothelial cell injury, inflammation,
and coagulation. Infection of pulmonary alveolar cells causes
severe endothelial injury and is marked by a local inflamma
tory infiltrate and microthrombi.8 Microthrombi in alveolar
capillaries and vascular congestion were present in nearly
45% of patients who died from acute respiratory complica
tions due to COVID19.9 Alveolar capillary microthrombi were
9 times more prevalent in those who died from COVID19
infection compared to similar severe H1N1 infections, and
increased thrombotic complications were mostly noted in
those with longer hospital stays.8 In severe infection, this
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Table 1. Risk factors to remember in COVID-19-related thrombosis4,37
COVID-19 infection

COVID-19 (adenovirus) vector vaccines

Older age (>75)

Middle age (18-49)

Male

Female

Obesity

Platelet count <150

Hypertension

Splanchnic vein and cerebral vein thrombosis reported in higher rates

Prior cardiac disease
Active cancer or recent anticancer treatment
Elevated D-dimer, FDP, LA

immune response can be exaggerated and cause systemic hyper
inflammation, marked by high lev
els of proinflammatory cyto
kines.10,11 The down
stream effects of endo
the
lial cell acti
va
tion
and a systemic inflammatory response include a hypercoagulable
state and both micro- and macrovascular thrombosis, with multi
ple interrelated mechanisms.

Activation of endothelial cells, platelets,
and leukocytes
Direct infection of vascular endothelial cells with resultant apopto
sis has been described in an autopsy series of COVID-19 patients.12
This, along with complement activation,13 contributes to a local
inflammatory reaction and further endothelial cell activation, with
the expression of tissue factor, release of von Willebrand factor
(VWF), and decreased synthesis of nitric oxide and prostacyclin,14
all of which promote coagulation. An increase in VWF coupled
with a relative imbalance in ADAMTS-13 has been demonstrated
in patients with COVID-19 of varying severity,15 and elevated VWF
antigen and low ADAMTS-13 activity seem to correlate with the
development of VTE.16 Platelet acti
va
tion increases in severe
COVID-19 infection, triggering increased tissue factor expression
and coagulation.14,17,18 Similarly, neutrophil activation increases, with
the release of neutrophil extracellular traps that promote thrombo
sis in these patients.19

increases the likelihood of development of heparin-induced
thrombocytopenia (HIT), another potential etiology of VTE in
these patients. Rates of HIT in severe COVID-19 infection are
variable across studies, with rates ranging from 0.16% in all
admitted patients to 8.1% in an ICU population. Anti-platelet
factor 4 (PF4) antibodies are frequently detected even in the
absence of clinical HIT,21,22 and 1 group has demonstrated nonheparin-dependent platelet-activating immune complexes that
may contribute to thrombosis.23

Antiphospholipid antibodies
A final poten
tial mech
a
nism for throm
bo
sis in patients with
COVID-19 is the development of antiphospholipid antibodies,
an appeal
ing the
ory given the hyperinflammatory response
and potential for antibody production. As many as 90% of crit
ically ill patients have been found to be positive for a lupus
anticoagulant (LA).24,25 The clinic
 al significance of this is unclear,
as an association with thrombosis has not been consistently
demonstrated,25 assays may be sus
cep
ti
ble to inter
fer
ence
by C-reactive protein and unfractionated heparin, and rates
of anticardiolipin and anti-β2-glycoprotein seem to be signif
icantly lower.24-26 However, 1 study at a tertiary care center in
the US found a significant association between LA positivity
and venous or arterial thrombosis.26

Coagulation and fibrinolysis
The increase in tis
sue fac
tor expres
sion on a vari
ety of cells
induces extrinsic coagulation pathway activation, while the
release of factor VIII from damaged endothelium, NETosis, and
platelet and complement activation all contribute to intrinsic
pathway activation. These events result in thrombin genera
tion and the formation of a fibrin clot. COVID-19 infection is also
marked by high levels of fibrinogen,10,11 an acute phase reactant,
and the inhibition of fibrinolytic pathways. Patients with severe
infection and shutdown of fibrinolysis—as measured by a lack
of clot lysis on viscoelastic testing—were found to have greater
dimerized plasmin fragment D (D-dimer) and fibrinogen levels
and a significantly greater incidence of clinical VTE (Table 1).20

Heparin-induced thrombocytopenia
Given the propensity for thrombosis, patients admitted with
COVID-19 are frequently managed with anticoagulation prophy
laxis. This, combined with the systemic inflammatory response,
622 | Hematology 2021 | ASH Education Program

CLINICAL CASE (Continued)
Our patient was a real one and in fact is the senior author of this
article. He received prophylactic-dose enoxaparin while on the
medical floor.

Anticoagulation prophylaxis
When choosing a prophylactic approach, the risk of bleeding must
be considered, particularly if the platelet count is <50 000, and
mechanical prophylaxis is likely the best approach until the bleed
ing risk abates. The dose and choice of anticoagulant also depend
on renal func
tion, and it may be rea
son
able to give “obe
sityadjusted” doses—eg, enoxaparin 40mg twice daily or a daily total
dose of 0.5mg/kg based on limited evidence.27 Of note, obesityadjusted prophylactic dosing differs from intermediate dosing.
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VTE in lower-extremity deep veins and PE commonly seen
FDP, fibrin degradation products.

Noncritically ill patients

aban (20mg or renally adjusted 15mg daily) for 30 days or standard
VTE prophylaxis.31 Clinically unstable patients (10%) randomized to
rivaroxaban first received enoxaparin or unfractionated heparin
(1 patient) followed by rivaroxaban when clinically stable. Patients
randomized to standard prophylaxis primarily received enoxaparin
(84%), and 13% continued postdischarge prophylaxis at their clini
cian’s discretion. The hierarchical analysis of time to death, dura
tion of hospitalization, and duration of supplemental oxygen was
performed using the win ratio, and there was no difference in effi
cacy with a win ratio of 0.86; P = .40. There was also no difference in
each component of this composite outcome or thromboembolic
event. However, major or clinically relevant nonmajor bleeding
was increased with therap
 eutic anticoagulation (8%) compared to
standard dosing (2%) with a relat ive risk of 3.64 ( P = .001).
Until the 3 mpRCTs are fully published, it is reasonable to use
either therap
 eutic or prophylactic doses of LMWH (preferred if
renal function is acceptable) or heparin. Direct oral anticoagu
lants (DOACs) should not be used unless there is another indica
tion, such as atrial fibrillation.

How we treat noncritically ill hospitalized patients
We discuss the risks and benefits of prophylactic vs ther
apeutic doses of anticoagulation and their impact on the
need for organ support in noncritically ill patients hospital
ized with COVID-19. We use therapeutic dosing of LMWH
or unfractionated heparin based on these early results and
eagerly await peer-reviewed pub
li
ca
tion and guide
line
updates.

CLINICAL CASE (Continued)
Oxygen require
ment increased for our patient, and a high
flow was needed with transfer to the ICU, where LMWH was
increased to intermediate dose. Several days later, intubation

Figure 1. ASH recommendations for VTE prophylaxis in COVID patients with critical illness. Reproduced with permission from
Cuker et al.28
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The Amer
i
can Society of Hematology (ASH) draft guide
lines (updated 8 February 2021) suggest prophylactic over
intermediate- or therapeutic-dose anticoagulation for patients
with acute (not critical) illness and acknowledge pending results
of the combined analysis of the REMAP-CAP, ACTIV-4, and ATTAC
multiplatform randomized controlled trials (mpRCT).28 These
3 mpRCTs harmonized their protocols to accelerate the battle
against COVID-19 infection and reported their pooled results in
separ ate papers for critically ill and noncritically ill patients.29,30
The first patient was randomized on 21 April 2020, and these
tri
als were stopped on 22 Jan
u
ary 2021. The pre
print report
appeared on 17 May 2021 when the prespecified superiority stop
ping rule threshold was attained.30 The primary analysis popula
tion had 2219 participants with confirmed COVID-19 who did not
require ICU-level organ support, which was defined as high-flow
oxygen, mechanical ventilation (invasive or noninvasive), vasopres
sors, or inotropes. They were randomized in an open-label man
ner to therapeutic-dose heparin (94.7% received LMWH, mostly
enoxaparin) or usual care thromboprophylaxis (71.7% low dose
and 26.5% intermediate dose) for up to 14 days. The primary out
come of survival to hospital discharge without organ support (as
defined above) through 21 days occurred in 76.4% of participants
receiving the usual care and increased by 4.6% with therapeuticdose anticoagulation, with a median adjusted odds ratio of 1.29%
and a 99% probab
 ility of the therapeutic dose being effective. The
probability of survival to hospital discharge with therapeutic-dose
heparin was 87.1%, with a median absolute improvement of 1.3%.
Major bleeding occurred in 1.9% and 0.9% of therapeutic-dose and
usual care participants, respectively. A prespecified analysis based
on D-dimer levels showed a slightly better probability of superior
ity in patients with high levels (97.3%) vs low levels (92.9%).
The ACTION trial randomized 615 hospitalized patients (who
were primarily stable and not critically ill) in 31 Brazilian sites with
ele
vated D-dimer lev
els above the upper limit of nor
mal from
24 June 2020 to 26 February 2021 to therapeutic doses of rivarox

and mechanical ventilation were required. Meanwhile, the
patient’s father was also critically ill with COVID-19, and his cli
nicians used therapeutic-dose LMWH: 2 patients with the same
last name, 1 floor apart, with different doses to prevent the
same complications—all were searching for evidence.

Critically ill patients
ASH guidelines suggest prophylactic- over intermediate-dose
anticoagulation in critically ill patients, and recommendations
for therapeutic dose vs prophylactic dose are forthcoming
(Figure 1).

How we treat critically ill patients
We use prophylactic- and not intermediate- or therapeuticdose LMWH or heparin in critically ill patients with COVID-19.

CLINICAL CASE (Continued)
After a couple of weeks in the ICU with respiratory failure and
septic shock, our patient was extubated but suffered a small PE
while his central line was being removed. He was treated for

Table 2. List of selected anticoagulation trials in COVID-19
Patient
population

Trial name and
trial identifier Intervention

Hospitalized
(non-ICU)

ACTION Trial

Therapeutic rivaroxaban
or LMWH

Usual care thromboprophylaxis Mortality, length of stay, and oxygen use

Published

ATTACC30
NCT04372589

Therapeutic heparin
or LMWH

Usual care thromboprophylaxis Hospital discharge without need for
organ support

Preprint

ACTIV-4a30
NCT04505774

Therapeutic heparin
or LMWH

Usual care thromboprophylaxis Hospital discharge without need for
organ support

Preprint

REMAP-CAP30
NCT02735707

Therapeutic heparin
or LMWH

Usual care thromboprophylaxis Hospital discharge without need for
organ support

Preprint

ATTACC29
NCT04372589

Therapeutic heparin
or LMWH

Usual care thromboprophylaxis Hospital discharge without need for
organ support

Preprint

ACTIV-4a29
NCT04505774

Therapeutic heparin
or LMWH

Usual care thromboprophylaxis Hospital discharge without need for
organ support

Preprint

REMAP-CAP29
NCT02735707

Therapeutic heparin
or LMWH

Usual care thromboprophylaxis Hospital discharge without need for
organ support

Preprint

INSPIRATION32
NCT04486508

Intermediate-dose
heparin or LMWH

Prophylactic-dose heparin or
LMWH

Composite of VTE, arterial thrombosis,
or ECMO

Published

Post discharge ACTIV-4
Convalescent
NCT04650087

Prophylactic-dose
apixaban

Placebo

Composite outcome of symptomatic DVT,
PE, other VTE, ischemic stroke, acute
MI, other ATE, and all-cause mortality

Recruiting

Outpatient

ACTIV-4c
NCT04498273

Prophylactic-dose
apixaban, therapeuticdose apixaban, ASA

Placebo

Composite of symptomatic DVT or PE,
ATE, MI, ischemic stroke, hospitalization
for cardiovascular/pulmonary events,
and all-cause mortality

Recruiting

PREVENT-HD
NCT04508023

Prophylactic-dose
rivaroxaban

Placebo

Composite of symptomatic VTE, MI,
ischemic stroke, systemic embolism,
acute limb ischemia, all-cause
hospitalization, and all-cause mortality

Recruiting

Hospitalized
(ICU)

31

Comparison

ASA, aspirin; ECMO, extracorporeal membrane oxygenation; MI, myocardial infarction.
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Outcome

Status

Downloaded from http://ashpublications.org/hematology/article-pdf/2021/1/621/1852155/621thilagar.pdf by guest on 14 February 2022

Therapeutic dose. Data for critically ill participants randomized
while receiving organ support as previously described in the
3 mpRCTs were posted on 12 March 2021.29 This prespecified
cohort stopped recruit
ment for crit
i
cally ill patients on 19
December 2020 because of futility. The primary outcome of sur
vival until discharge and the median number of organ-supportfree days was 3 in those randomized to therap
 eutic-dose LMWH
or heparin and 5 days with the usual care (41% prophylacticdose and 51% intermediate-dose LMWH or heparin; adjusted
odds ratio, 0.87; 95% credible interval, 0.70-1.08; likelihood of
not achieving meaningful relat ive improvement of at least 20%,
99.8%).

Intermediate dose. Among 600 randomized COVID-19 patients in
the ICU, 562 were included in the primary analysis of the INSPIRATION
trial.32 Intermediate enoxaparin doses of 1mg/kg once daily vs
40mg daily (with adjustment for weight and creatinine clearance)
were compared for the primary composite efficacy outcome of
venous or arterial thrombosis, treatment with extracorporeal
membrane oxygenation, or mortality. No differences were noted in
30-day outcomes between intermediate and prophylactic doses
(45.7% vs 44.1%; odds ratio, 1.06; P = .70). Major bleeding occurred
in 2.5% and 1.4% of patients who received inter
me
di
ate and
prophylactic dosing, respectively, and the risk difference failed
to meet the noninferiority margin. Severe thrombocytopenia
occurred in 6 patients, allof whom received an intermediate dose.

3 months with a DOAC, which precluded the decision regard
ing post-hospital discharge anticoagulant prophylaxis.

Postdischarge prophylaxis
This patient had symptoms of PE with acute chest pain and
worsened hypoxemia and was stable for computed tomogra
phy, rendering a straightforward workup. We only pursue diag
nosing VTE based on clinical suspicion and do not screen or
use D-dimer thresholds to screen in accordance with guidance
statements.33

As discussed previously, rates of VTE are relatively low post
hospitalization; however, mitigation of arterial and VTE along
with reductions in all-cause mortality deserves investigation. A
prospective registry of 4906 patients with COVID-19 were con
tacted a mean of 92 days after discharge, and 1.55% developed
VTE, arterial thromboembolic events (ATE) occurred in 1.71%,
and all-cause mor
tality was 4.83%. There was a 46% relative
reduction in the composite outcome of VTE, ATE, and mortality
(P=.0046) in the multivariable analysis.34 The ACTIV-4b National
Institutes of Health-sponsored trial is investigating whether apix
aban at prophylactic or therapeutic doses and low-dose aspirin,
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Figure 2. VITT diagnostic flowchart from ISTH interim guidance published 20 April 2021. aPTT, activated partial thromboplastin time;
IVIG, intravenous immunoglobulin, PT, prothrombin time. Reproduced with permission from the ISTH.41
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compared to placebo, can reduce these complications after hos
pitalization. The studies are summarized in Table 2.
The US Food and Drug Administration has approved rivarox
aban and betrixaban for postdischarge VTE prophylaxis; how
ever, betrixaban is not commercially available. The prophylactic
dose of 10mg of rivaroxaban for a total of 31 to 39 days has been
approved but should not be used in patients with creatine clear
ance less than 30 mL/min, with drug-drug interactions and high
bleeding-risk conditions.27

How we treat patients after discharge

“Prehospitalization” prophylaxis
The trial results above suggest that higher doses of anticoag
ulation are not effective late in the disease course, and it is a
reasonable hypothesis that anticoagulation very early in the dis
ease may be beneficial to decrease immuno-micro pulmonary
thrombosis. Two trials with DOACs are underway to help answer
this question (Table 2).

How we treat nonhospitalized outpatients
We do not use anticoagulation prophylaxis early in COVID19 for patients who do not require hospitalization.

Postvaccination: vaccine-induced immune thrombotic
thrombocytopenia
The approval and widespread administration of vaccines for
COVID-19 brought yet another element into the discussion of
COVID-19 and thrombosis. Vaccine-induced immune thrombotic
thrombocytopenia (VITT) or thrombosis with thrombocytopenia
syndrome is the name given to the thrombotic complications
currently being reported across the world following the admin
istration of the adenovirus vector vaccines (ChAdOx1 nCoV-19
[AstraZeneca/COVIDSHIELD] and Ad26.COV2.S [Johnson and
Johnson/Janssen]) against SARS-CoV-2.35 The underlying path
ophysiology of VITT is not fully understood. One hypothesis is
that the polyanionic constituents of the adenovirus vector vac
cines cause the formation of antibodies to PF4. These antibodies
against PF4 then induce platelet activation, causing both throm
bocytopenia and thrombosis. VITT is similar to autoimmune hep
arin-induced thrombocytopenia (aHIT), with the presence of
anti-PF4 polyanion antibodies inducing platelet activation in the
absence of and independently of heparin exposure; however,
VITT and aHIT differ in the distribution of the thrombi.36,37
VITT generally presents between 4 to 30 days after initial vac
cination with either adenovirus vector vaccine.35 Early reports
showed that VITT primarily presented in younger females. Data
on the incidence range from 1 case per 26 000 to 1 case per
127 000 doses of ChAdOx1 nCoV-19 vaccine administered and
1 case per 500 000 doses of the Ad26.COV2.S. No specific risk
factors have been identified. In VITT, thrombosis tends to mani
fest in rare sites, most notably in the cerebral venous sinuses and
in the splanchnic and hepatic veins.35,38

626 | Hematology 2021 | ASH Education Program

Conclusion
The thromboembolic burden of COVID-19 seems to be decreas
ing as the pandemic evolves, and a multitude of mechan
 isms
are purported to explain the elevated risk with this infection.
Key to understanding the timing, dosing, and patient setting for
prophylaxis is an appreciation of immune-induced inflammatory
microthrombosis. Robust randomized trials are the best tools to
understand the appropriate use of anticoagulation to prevent
thromboembolic complications, and the final results of many
ongoing studies are eagerly awaited.
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